Chairman & CEO - Arcellx
YesPress Profile
Chairman & Chief Executive Officer - Arcellx (NASDAQ: ACLX)
"Privilege is not the presence of an advantage. It's the absence of an impediment."
The Profile
In 2001, Rami Elghandour wrote firmware for implantable spinal cord stimulators at a company called Advanced Neuromodulation Systems. The code he shipped went inside people's bodies. Every line mattered. That particular relationship with precision - the kind where mistakes have physical consequences - never left him, even as his career arced outward from circuits to capital markets to cutting-edge cancer biology.
Two decades later, he runs Arcellx, a clinical-stage biotech in Redwood City whose BCMA-targeting CAR-T therapy anito-cel posted a 97% overall response rate in relapsed or refractory multiple myeloma - a number that made oncologists stop scrolling. The company he joined in January 2021 as a lean, early-stage startup had reached a peak valuation above $6 billion by 2024. He did something similar at Nevro, where he scaled headcount from 30 to nearly 1,000 people and pushed annual revenue toward $400 million before moving on.
The short version: Rami Elghandour finds undercapitalized innovations in medical technology, runs toward them, and builds durable companies around them. The longer version involves a Wharton MBA, two U.S. patents, a spell as a J&J venture capitalist, and a side career as an Oscar-nominated film producer. Neither version is complete without his conviction that the people you put in the room matter as much as the science itself.
"90% done, 90% to go."
Rami Elghandour - engineering principle turned leadership philosophyThat phrase - borrowed from the hard-won reality of engineering projects - is the one his colleagues hear most often. It describes how he paces everything: the assumption that the final fraction of any hard problem holds most of the actual work. It's an unusual thing for a CEO to internalize. Most leaders celebrate progress; Rami recalibrates to what remains.
The Science
CAR-T therapy - chimeric antigen receptor T-cell therapy - works by taking a patient's own immune cells, engineering them in a lab to recognize cancer, and reinfusing them. The results in blood cancers have been remarkable. The limitations have been just as real: narrow indications, safety concerns, difficult manufacturing, and a therapeutic window that can close fast.
Arcellx's answer is the D-domain scaffold. Unlike conventional antibody-based binding domains used in most CAR-T therapies, the D-domain is a small synthetic protein binder engineered specifically for stability and precision. Anito-cel - the lead program targeting BCMA on multiple myeloma cells - showed a 97% overall response rate and 93.1% MRD-negative rate in Phase 2. MRD-negative means cancer is undetectable in the bone marrow. That's the number that matters. Elghandour put it plainly: "The data strongly support what we believe is a best-in-class profile for this cell therapy."
The platform doesn't stop at myeloma. ARC-SparX is Arcellx's next-generation controllable cell therapy system - designed to extend the reach of engineered T cells into indications that have historically resisted them, including acute myeloid leukemia and solid tumors. The "controllable" part is the key innovation: the ability to modulate cell activity after infusion, which directly addresses safety and durability concerns that have limited older CAR-T approaches.
Arcellx partnered with Kite (a Gilead company) to co-develop CART-ddBCMA, combining Arcellx's D-domain technology with Kite's manufacturing and commercial infrastructure. The BLA filing is on the horizon; commercial launch is targeted for 2026.
"With ARC-SparX, we believe we can get into more difficult-to-treat indications. For example, we're going after acute myeloid leukemia next."
Rami Elghandour on expanding the Arcellx platformFor a company that was an early-stage startup when Elghandour arrived in 2021, the trajectory is unusual. Most biotechs at that stage are still fighting for their first meaningful clinical signal. Arcellx is now filing for approval in a major indication while simultaneously running next-generation programs in harder cancers. The engineering principle applies here too: 90% done, 90% to go.
By the Numbers
The Journey
Graduates from Rutgers University with a BS in Electrical and Computer Engineering. Joins Advanced Neuromodulation Systems as a Design Engineer, writing firmware for implantable spinal cord stimulators. This is where the "every line matters" mentality gets wired in.
Enters Wharton School at University of Pennsylvania for an MBA in Healthcare Management. The engineer pivots toward business - but keeps both patents from his engineering years (issued 2007 and 2010), covering implantable device communication systems.
Joins Johnson & Johnson Development Corporation (JJDC) as an investor. Leads investments across devices, biotech, and consumer products. Crucially, leads Nevro's Series B financing and joins Nevro's board - the same company he will later run.
Becomes President and CEO of Nevro Corporation, the neuromodulation company he'd invested in from J&J. Begins the transformation from 30-person startup to public company. The investor-turned-operator arc is complete.
Leads Nevro's IPO. Raises over $700M total through venture capital, IPO, and follow-on offerings. Orchestrates a product launch that generates $320 million in sales within 3.5 years. Peak valuation exceeds $3 billion - a 10x+ increase.
Receives the Bill Campbell "Man Who Gets It" award from Watermark, a leading women's organization - recognition not for what he built, but for how he built it. Nevro consistently ranked among the best companies for women and diversity.
January 22: Appointed Chairman and Chief Executive Officer of Arcellx. Joins a small, early-stage biotech developing a novel D-domain scaffold for cell therapy. The company's potential is evident in its science; the commercial path is still to be built.
Arcellx goes public on NASDAQ (ACLX). Phase 2 data for anito-cel returns a 97% overall response rate in relapsed/refractory multiple myeloma. The number travels fast in oncology circles. The partnership with Kite/Gilead advances.
Arcellx reaches a peak valuation exceeding $6 billion - a 30x+ increase under Elghandour's leadership. He also executive-produces "The Voice of Hind Rajab," which receives an Oscar nomination for Best Documentary Short. Both simultaneously.
Presents iMMagine-1 study results at EHA 2025. BLA filing for CART-ddBCMA in progress; commercial launch targeted for 2026. The ARC-SparX platform advances toward AML and solid tumor indications. The race continues.
The Leader
CNBC ranked Elghandour #7 among the best CEOs for women. USA Today put him #11 for diversity and #18 overall among large-company CEOs. These rankings emerged from culture that was built intentionally, not accidentally - from the daily decisions about who gets hired, promoted, and heard.
His TEDx talk, "Why bias, not behavior or ability, is holding women back," laid out the structural argument: it's not a pipeline problem. His companies have been test cases for the alternative thesis.
Elghandour's core leadership principle is not about pace or ambition. It's about completion: the discipline to see things through past the point where most people stop. The engineering adage "90% done, 90% to go" is its technical expression.
In practice, it shows up as a leadership style that resists declaring victory early and keeps attention on what's actually unfinished - whether that's a clinical trial, a culture initiative, or a regulatory filing.
Elghandour serves on nonprofit boards focused on education, gender equity, and humanitarian impact. He is a startup advisor, guest lecturer, and judge for the EY Entrepreneur of the Year program - channeling the operator experience back into the ecosystem that shaped him.
At Action Potential Venture Capital, where he spent time as Executive in Residence, he bridged the investor and operator perspectives he'd held separately across his career.
In His Own Words
"Privilege is not the presence of an advantage. It's the absence of an impediment."
"The data strongly support what we believe is a best-in-class profile for this cell therapy, especially given its impressive 97% overall response rate and 93.1% MRD-negative response rate."
"Cell therapies are obviously a very innovative and very impactful technology, but they've historically been very limited in their use."
"With ARC-SparX, we believe we can get into more difficult-to-treat indications. For example, we're going after acute myeloid leukemia next."
"Always finish the race."
"90% done, 90% to go."
In 2024, while filing clinical data for a potential FDA-approved cancer therapy, Rami Elghandour was also credited as executive producer of "The Voice of Hind Rajab" - a documentary short that went on to receive an Oscar nomination. The film follows the story of Hind Rajab, a Palestinian child who became a symbol of the conflict in Gaza.
That same period, he produced "American Doctor," which premiered at the Sundance Film Festival. The combination - NASDAQ CEO, humanitarian film producer, TEDx speaker on gender bias - is genuinely unusual. He describes his passions as photography, writing, art, music, and social advocacy. The biotech is the job; these are the person.
His Instagram handle is @zainydad - a detail that positions family first, long before the board titles and market caps.
Other Dimensions
"Why bias, not behavior or ability, is holding women back" - a structural case for gender equity from a male CEO
Oscar-nominated "The Voice of Hind Rajab" + Sundance premiere "American Doctor"
Two U.S. patents for implantable device technology (2007, 2010) - predating his MBA and CEO career
Photography, writing, art, music, AI, cryptocurrency, virtual reality, autonomous driving
Recognition
EY Entrepreneur of the Year - Northern California winner and National Finalist
Led two successful IPOs: Nevro (NYSE) and Arcellx (NASDAQ: ACLX)
Raised over $1.75 billion in capital across a career spanning MedTech and biotech
#7 Best CEO for Women (CNBC) - ranking built through deliberate culture, not PR
#11 Best CEO for Diversity (USA Today) and #18 among top 50 large-company CEOs
Bill Campbell "Man Who Gets It" Award from Watermark (2018) for advocacy on women's issues
Diversity Woman Magazine Game Changer - Male Ally Award (2021)
BLOC 100 Champion Award for diversity and inclusion leadership
Executive producer of Oscar-nominated "The Voice of Hind Rajab" (2024)
Executive producer of "American Doctor" - Sundance Film Festival premiere
Holds two U.S. patents for implantable medical device communication systems
TEDx speaker: "Why bias, not behavior or ability, is holding women back"
Education
Healthcare Management, 2006-2008. The MBA reframed the engineer's mindset toward capital allocation, organizational scale, and market strategy. Elghandour entered Wharton with patents to his name and came out with a framework for building companies around disruptive medical technologies.
Class of 2001. The foundational degree that shaped how he thinks about precision, failure modes, and what "done" actually means. "90% done, 90% to go" is engineering knowledge - and it's the phrase that follows him into every company he runs.